Paradigm Financial Partners LLC Has $2.01 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Paradigm Financial Partners LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.2% during the fourth quarter, Holdings Channel reports. The institutional investor owned 24,771 shares of the biopharmaceutical company’s stock after acquiring an additional 533 shares during the quarter. Paradigm Financial Partners LLC’s holdings in Gilead Sciences were worth $2,007,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of GILD. PGGM Investments lifted its holdings in shares of Gilead Sciences by 10.7% during the fourth quarter. PGGM Investments now owns 87,067 shares of the biopharmaceutical company’s stock valued at $7,053,000 after acquiring an additional 8,382 shares during the period. Alliance Wealth Advisors LLC UT lifted its holdings in shares of Gilead Sciences by 14.0% during the fourth quarter. Alliance Wealth Advisors LLC UT now owns 23,992 shares of the biopharmaceutical company’s stock valued at $1,944,000 after acquiring an additional 2,938 shares during the period. Private Wealth Partners LLC lifted its holdings in shares of Gilead Sciences by 14.9% during the fourth quarter. Private Wealth Partners LLC now owns 44,891 shares of the biopharmaceutical company’s stock valued at $3,637,000 after acquiring an additional 5,827 shares during the period. Citizens Financial Group Inc. RI lifted its holdings in shares of Gilead Sciences by 49.6% during the fourth quarter. Citizens Financial Group Inc. RI now owns 5,164 shares of the biopharmaceutical company’s stock valued at $418,000 after acquiring an additional 1,711 shares during the period. Finally, Kovack Advisors Inc. lifted its holdings in shares of Gilead Sciences by 7.0% during the fourth quarter. Kovack Advisors Inc. now owns 10,495 shares of the biopharmaceutical company’s stock valued at $850,000 after acquiring an additional 685 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Buying and Selling

In other news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the transaction, the insider now owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Up 0.2 %

Shares of NASDAQ:GILD traded up $0.15 during mid-day trading on Friday, hitting $65.42. 12,382,425 shares of the company traded hands, compared to its average volume of 6,443,315. The stock has a market cap of $81.45 billion, a P/E ratio of 181.72, a P/E/G ratio of 1.17 and a beta of 0.19. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a 12-month low of $64.63 and a 12-month high of $87.86. The stock has a 50-day moving average price of $71.28 and a two-hundred day moving average price of $76.25.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The business had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a return on equity of 23.08% and a net margin of 1.76%. Gilead Sciences’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period last year, the company posted $1.37 earnings per share. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 3.82 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be issued a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.71%. Gilead Sciences’s dividend payout ratio (DPR) is currently 855.56%.

Analyst Ratings Changes

A number of research firms recently issued reports on GILD. Cantor Fitzgerald cut their price target on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a report on Wednesday, February 7th. Morgan Stanley lowered their price objective on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a research report on Friday. Truist Financial lowered Gilead Sciences from a “buy” rating to a “hold” rating and decreased their target price for the stock from $91.00 to $82.00 in a research report on Thursday, February 22nd. TD Cowen dropped their price objective on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Friday. Finally, StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $83.87.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.